Ischemic Stroke Clinical Trial
Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST). A Randomised-controlled Trial of Thrombolytic Treatment With Tenecteplase for Acute Ischaemic Stroke Upon Awakening
|Source||University Hospital of North Norway|
|Contact||Melinda B Roaldsen, MD|
|Status||Not yet recruiting|
|Start date||June 12, 2017|
|Completion date||December 31, 2022|
Stroke is a leading causes of death and disability. At least 20% of strokes occur during
sleep, so- called 'wake up stroke'. Thrombolysis with the clot-busting drug alteplase is
effective for acute ischaemic stroke, provided that it is given within 4.5 hours of symptom
onset. Patients with wake-up stroke are currently ineligible for clot-busting therapy.
Previous studies indicate that many wake-up strokes occur just before awakening.
In this study, patients with wake-up stroke will be randomized to thrombolysis with tenecteplase and best standard treatment or to best standard treatment without thrombolysis. Tenecteplase has several potential advantages over alteplase, including very rapid action and that it can be given as a single injection. Prior to thrombolysis, a brain scan must be done to exclude bleeding or significant brain damage as a result from the stroke. We will use a CT scan to inform this decision. CT is used as a routine examination in all stroke patients. Other studies testing clot-busting treatment in wake-up stroke are using alteplase and more complex brain scans, which are not routinely available in the emergency situation in all hospitals.
One in five strokes occur during sleep, but patients with "wake-up" stroke are not given thrombolytic therapy because time of stroke onset is unknown. On-going trials are testing alteplase, and use MRI techniques for selection of patients. Tenecteplase has many pharmacological advantages over alteplase: greater fibrin specificity, very rapid action, longer half-life, and single bolus administration. In addition, patient selection based on MRI findings risks excluding many patients that might otherwise benefit. TWIST will test tenecteplase and will not use MRI techniques for selection of patients. Plain CT and CT angiography (if possible) will be performed before randomisation, and CT perfusion will be performed at selected centres, as part of a sub-study.
Study design: TWIST is an international, multi-centre, randomised, open-label, blinded-endpoint trial of tenecteplase for acute ischaemic 'wake-up' stroke.
1. Can tenecteplase given <4.5 hours of awakening improve functional outcome at 3 months?
2. Can findings on cerebral plain CT and CT angiography (and CT perfusion, at selected centres) identify patients who benefit from such treatment, compared to other patients?
Patients eligible for treatment who are able to receive tenecteplase within 4.5 hours of waking, will be randomly allocated to treatment with tenecteplase in addition to best standard treatment, versus best standard treatment.
Randomisation and treatment: Central randomisation (over the internet) to tenecteplase 0.25 mg/mg i.v. (maximum dose 25 mg) plus best medical treatment vs. best medical treatment alone.
Imaging: All patients will undergo CT and CT angiography (CTA, if possible) before randomisation and on day 2. CT perfusion (CTP) will be performed at selected centres, as part of a sub-study.
Follow-up and primary effect variable: Centralised follow-up via telephone or mail at 3 months. The primary effect variable is functional outcome (modified Rankin Scale score).
Study size and centers: 500 patients from centers in Norway, Sweden, Denmark, Finland, Estonia, Lithuania, United Kingdom and Switzerland.
|Not yet recruiting||NCT02912663 - Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.||Phase 1|
|Recruiting||NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders||N/A|
|Recruiting||NCT02785120 - A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes||Phase 2|
|Completed||NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects||Phase 1|
|Withdrawn||NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke||N/A|
|Recruiting||NCT03041753 - Reperfusion Injury After Stroke Study||N/A|
|Active, not recruiting||NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial||Phase 4|
|Recruiting||NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial||Phase 2|
|Active, not recruiting||NCT02232022 - Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke||N/A|
|Completed||NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke||N/A|
|Recruiting||NCT02924168 - Radial Shock Waves for Functional Disability in Stroke||N/A|
|Recruiting||NCT01983644 - RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study||N/A|
|Recruiting||NCT01852201 - POSITIVE Stroke Clinical Trial||N/A|
|Completed||NCT01968122 - Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China||N/A|
|Not yet recruiting||NCT01923818 - Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events||Phase 2/Phase 3|
|Recruiting||NCT02184936 - Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke||N/A|
|Completed||NCT01949948 - Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke||Phase 3|
|Recruiting||NCT01526824 - Lovaza's Effect on Clopidogrel in a Neuro Population||Phase 0|
|Active, not recruiting||NCT02121327 - The Effects of Disease Management Programs for Prevention of Recurrent Ischemic Stroke||N/A|
|Active, not recruiting||NCT01193569 - A Study of Survival and Outcome After Stroke||Phase 4|